FIELD: chemistry.
SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining GLP-2 analogues, and can be used in medicine for treating GLP-2-associated disorders. The analogues of GLP-2 with agonistic activity with respect to GLP-2 receptors have been obtained.
EFFECT: invention makes it possible to increase resistance to proteases, which provides the lower clearance of the obtained analogues and prolongation of their bioavailability in comparison with native GLP-2.
29 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GLP-2 PEPTIBODY FOR INTRODUCTION BEFORE, DURING OR AFTER SURGICAL INTERVENTION | 2018 |
|
RU2795594C2 |
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| GLP-1 ANALOGS | 1999 |
|
RU2288232C9 |
| DOSING SCHEMES FOR ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE 2 (GLP-2) ANALOGUES | 2018 |
|
RU2785662C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| METHOD OF GLP-1 MOLECULES INTRODUCTION | 2003 |
|
RU2332229C2 |
| PHARMACEUTICAL COMPOSITIONS OF hGLP-1, EXENDIN-4 AND THEIR ANALOGUES | 2007 |
|
RU2419452C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
